Allergan ($AGN) has been on quite the buyout spree lately, and with $40.5 billion coming in from Teva ($TEVA) in exchange for its generics unit, it's about to settle some debt and get back to the dealmaking table. Who's next on CEO Brent Saunders' list, though, is anyone's guess, and we want to know what you think. Weigh in below on who you think Allergan should buy next and why--and feel free to write in an option if you think there's a good choice that's missing. We'll tally up the votes and get back to you with the results soon. Carly Helfand (email | Twitter)